Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 7
Submit an article Journal homepage
2,308
Views
29
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats

Kathryn W. WoodburnAffymax Inc., Palo Alto, CA, USACorrespondence[email protected]
,
Christopher P. HolmesAffymax Inc., Palo Alto, CA, USA
,
Susan D. WilsonAclairo Pharmaceutical Development Group, Inc., Vienna, VA, USA
,
Kei-Lai FongAccellient Partners LLC, Waltham, MA, USA
,
Randall J. PressAptuit, Kansas City, MO, USA
,
Yuu MoriyaTakeda Pharmaceutical Company Ltd, Osaka, Japan
&
Yoshihiko TagawaTakeda Pharmaceutical Company Ltd, Osaka, Japan
 show all
Pages 660-670 | Received 19 Oct 2011, Accepted 09 Dec 2011, Published online: 22 Dec 2011

References

  • Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, Narhi L, Elliott S. (2009). Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 98:2198–2211.
  • Caliceti P, Veronese FM. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261–1277.
  • Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
  • Elmore SA. (2006). Histopathology of the lymph nodes. Toxicol Pathol 34:425–454.
  • Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW. (2006). Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34:1303–1311.
  • Garibotto G, Sofia A, Saffioti S, Bonanni A, Mannucci I, Verzola D. (2010). Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease. Clin Nutr 29:424–433.
  • Greaves P, Faccini JM. (1992). Haemopoietic and lymphatic systems. In: Rat Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies. 2nd revised ed. Amsterdam: Elsevier Science Publishers B.V. pp 43–66.
  • Guiotto A, Canevari M, Pozzobon M, Moro S, Orsolini P, Veronese FM. (2004). Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg Med Chem 12:5031–5037.
  • Hamidi M, Azadi A, Rafiei P. (2006). Pharmacokinetic consequences of pegylation. Drug Deliv 13:399–409.
  • Im S, Fong K-L, Nishihara M, Takahashi J, Tagawa Y, Holmes CP, Woodburn KW. (2010). Hematide™/peginesatide is metabolically stable and does not induce or inhibit human cytochrome P450 enzymes. Poster presentation American Society of Nephrology Annual Meeting; 2010; Denver, Colorado. Abstract SA-PO2586 available on ASN website www.asn-online.org; published in J Am Soc Nephrol 21: 2010. p. 704A.
  • Jelkmann W. (2008). Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 141:287–297.
  • Juul SE, Yachnis AT, Christensen RD. (1998). Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235–249.
  • Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. (1997). Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520–527.
  • Katre NV. (1990). Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 144:209–213.
  • Krantz SB. (1991). Erythropoietin. Blood 77:419–434.
  • Lee HB, Blaufox MD. (1985). Blood volume in the rat. J Nucl Med 26:72–76.
  • Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S. (2004). Revised European best practice guideline for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 19:1–47.
  • Porter CJ, Edwards GA, Charman SA. (2001). Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50:157–171.
  • Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM. (2006). Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830–1834.
  • Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. (2007). PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9–16.
  • Woodburn KW, Schatz PJ, Fong KL, Wilson SD, Ferrell T, Spainhour CB, Norton D. (2008). Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys. Drug Chem Toxicol 31:229–244.
  • Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, Norton D. (2009). Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 104:155–163.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.